UK REACH Regulations SI 2019/758



Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	9373412-00007	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier					
Trade name	:	Gentamicin / Betamethasone Ointment Formulation			
1.2 Relevant identified uses of the substance or mixture and uses advised against					
Use of the Sub- stance/Mixture	:	Pharmaceutical			
Recommended restrictions on use	:	Not applicable			
1.3 Details of the supplier of the	e saf	ety data sheet			
Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain			
Telephone	:	+44 1 670 59 32 05			
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com			

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Reproductive toxicity, Category 1BH3Specific target organ toxicity - repeatedH3exposure, Category 1IorLong-term (chronic) aquatic hazard, Category 1eff

H360D: May damage the unborn child. H372: Causes damage to organs through prolonged or repeated exposure. H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Gentamicin / Betamethasone Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	-	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Haza	rd pictograms	:		¥
Signa	l word	:	Danger	•
Haza	rd statements	:	H372 (May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.
				Very toxic to aquatic life with long lasting effects.
Preca	autionary statements	:	Prevention:	
			P264 V P273 A P280 V	Obtain special instructions before use. Wash skin thoroughly after handling. Avoid release to the environment. Wear protective gloves/ protective clothing/ eye protection/ face protection.
			Response: P308 + P313	IF exposed or concerned: Get medical advice/ attention.
			P391 0	Collect spillage.

Hazardous components which must be listed on the label: betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Paraffin oil	8012-95-1 232-384-2	Asp. Tox. 1; H304 Aquatic Chronic 4; H413	5
Gentamicin	1403-66-3 215-765-8	Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	0.1

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Gentamicin / Betamethasone Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021	
			M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 1	
betam	nethasone	378-44-9 206-825-4	Acute Tox. 2; H330Repr. 1B; H360DSTOT RE 1; H372(Pituitary gland,Immune system,muscle, thymusgland, Blood, Ad-renal gland)Aquatic Chronic 1;H410M-Factor (Chronicaquatic toxicity):1,000specific concentra-tion limitSTOT RE 1; H372>= 0.01 %Repr. 1B; H360D>= 0.01 %	0.064

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures				
General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.		
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).		
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.		



Gentamicin / Betamethasone Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
In cas	se of skin contact	of water. Remove con Get medical Wash clothin	ntact, immediately flush skin with soap and plenty taminated clothing and shoes. attention. g before reuse. clean shoes before reuse.
In case of eye contact			rith water as a precaution. attention if irritation develops and persists.
lf swa	allowed	Get medical	DO NOT induce vomiting. attention. thoroughly with water.
4.2 Most i	mportant symptoms	and effects, both a	acute and delayed
Risks		: May damage	e the unborn child. age to organs through prolonged or repeated
4.3 Indica	tion of any immedia	te medical attentior	n and special treatment needed

SECTION 5: Firefighting measures

5.1 Extinguishing media		
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
5.2 Special hazards arising from	the	e substance or mixture
Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides
5.3 Advice for firefighters		
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment.



Gentamicin / Betamethasone Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021				
		•	y to cool unopened containers. naged containers from fire area if it is safe to do				
SECTION	SECTION 6: Accidental release measures						
6.1 Perso	nal precautions, prot	ective equipment and	d emergency procedures				
Perso	onal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro tective equipment recommendations (see section 8).					
6.2 Enviro	onmental precautions	5					
Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. If spillage enters rivers or watercourses, inform the Er ment Agency (emergency telephone number 0800 80							
6.3 Metho	ds and material for c	ontainment and clea	ning up				
Metho	ods for cleaning up	tainer for dispose Local or national posal of this ma employed in the	acuum up spillage and collect in suitable con- sal. al regulations may apply to releases and dis- aterial, as well as those materials and items e cleanup of releases. You will need to deter- ulations are applicable.				

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapours or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.



Gentamicin / Betamethasone Ointment Formulation

VersionRevision Date:5.006.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021		
Hygiene measures	 Take care to prevent of environment. If exposure to characteristic of the exposure to characteristic of the exposure to characteristic of the exposure of the effective operation of the effective operation of the exponent of the exponen	Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.		
7.2 Conditions for safe storage,	including any incom	patibilities		
Requirements for storage areas and containers		labelled containers. Store locked up. Keep fore in accordance with the particular national		
Advice on common storage	Strong oxidizing	ostances and mixtures		
7.3 Specific end use(s) Specific use(s)	: No data available	9		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis		
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)	Internal		
	Further inform	Further information: OTO				
betamethasone 378-44-9 T		TWA	1 μg/m3 (OEB 4)	Internal		
	Further inform	Further information: Skin				
		Wipe limit	10 µg/100 cm²	Internal		

Derived No Effect Level (DNEL):

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Paraffin oil	Workers	Inhalation	Long-term systemic effects	5 mg/m3
Π	Workers	Inhalation	Short-term exposure	5 mg/m3
	Workers	Inhalation	Long-term local ef-	5 mg/m3

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023	
5.0	06.04.2024	9373412-00007	Date of first issue: 27.08.2021	

		fects	
Workers	Inhalation	Acute local effects	5 mg/m3

Predicted No Effect Concentration (PNEC):

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 mg/kg food

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 14387 Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	 ointment No data available No data available No data available
рН	: No data available



Ver 5.0	sion	Revision Date: 06.04.2024		S Number: 73412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Melting point/freezing point		:	No data available	9	
Initial boiling point and boiling		:	No data available	9	
	range Flash p	point	:	No data available	9
	Evapor	ation rate	:	No data available	9
	Flamm	ability (solid, gas)	:	Not classified as	a flammability hazard
		explosion limit / Upper bility limit	:	No data available	9
		explosion limit / Lower bility limit	:	No data available	9
	Vapour	pressure	:	No data available	9
	Relativ	e vapour density	:	No data available	9
	Relativ	e density	:	No data available	9
	Density	/	:	No data available	9
	Solubili	ty(ies)			
		er solubility	:	No data available	
	Partitio	n coefficient: n-	:	No data available	9
		nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosi			NI I 2 VII	
	Visc	cosity, kinematic	:	No data available	2
	Explosi	ve properties	:	Not explosive	
	Oxidizii	ng properties	:	The substance o	r mixture is not classified as oxidizing.
9.2	Other ir	formation			
	Flamm	ability (liquids)	:	No data available	9
	Molecu	lar weight	:	No data available	9
	Particle	e size	:	No data available	9



Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	9373412-00007	Date of first issue: 27.08.2021

SECTION 10: Stability and reactivity

-	2		
10.	1 Reactivity		
	Not classified as a reactivity ha	aza	rd.
10.	2 Chemical stability		
	Stable under normal conditions	s.	
10.	3 Possibility of hazardous rea	ctio	ons
	Hazardous reactions	:	Can react with strong oxidizing agents.
10.	4 Conditions to avoid		
	Conditions to avoid	:	None known.
10.	5 Incompatible materials		
	Materials to avoid	:	Oxidizing agents
10.	6 Hazardous decomposition p	roc	ducts
	No hazardous decomposition p	oro	ducts are known.
SE	No hazardous decomposition p CTION 11: Toxicological inf		
		for	mation
	CTION 11: Toxicological inf 1 Information on toxicological Information on likely routes of	for ef	mation fects Skin contact
	CTION 11: Toxicological inf	for ef	mation
	CTION 11: Toxicological inf 1 Information on toxicological Information on likely routes of	for ef	mation fects Skin contact Ingestion
	CTION 11: Toxicological inf 1 Information on toxicological Information on likely routes of exposure	for ef	mation fects Skin contact Ingestion Eye contact
	CTION 11: Toxicological inf 1 Information on toxicological Information on likely routes of exposure Acute toxicity	for ef	mation fects Skin contact Ingestion Eye contact
	CTION 11: Toxicological inf 1 Information on toxicological Information on likely routes of exposure Acute toxicity Not classified based on availab	for ef	mation fects Skin contact Ingestion Eye contact
	CTION 11: Toxicological inf 1 Information on toxicological Information on likely routes of exposure Acute toxicity Not classified based on availab <u>Components:</u>	for ef	mation fects Skin contact Ingestion Eye contact information.

Gentamicin:

Acute oral toxicity	: LD50 (Rat): 8,000 - 10,000 mg/kg
	LD50 (Mouse): 10,000 mg/kg
Acute inhalation toxicity	 LC50 (Rat): > 0.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.

toxicity

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



ersion 0	Revision Date: 06.04.2024		9S Number: 73412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
11				
Acute toxicity (other routes of administration)		:	LD50 (Rat): 67 - 9 Application Route:	
			LD50 (Rat): 371 - Application Route:	
			LDLo (Monkey): 3 Application Route:	
II betar	nethasone:			
	e oral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg
			LD50 (Mouse): > 4	4,500 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): 0.4 m Exposure time: 4 ł	
Skin	corrosion/irritation			
Not c	lassified based on availa	ble	information.	
<u>Com</u>	ponents:			
Paraf	ffin oil:			
Speci Resu		:	Rabbit No skin irritation	
Genta	amicin:			
Speci Resu		:	Rabbit Mild skin irritation	
betar	nethasone:			
Speci	ies	:	Rabbit	
Resu	It	•	Mild skin irritation	
Serio	ous eye damage/eye irri	tati	on	
Not c	lassified based on availa	ble	information.	
Com	ponents:			
Paraf	ifin oil:			
Speci		:	Rabbit	
Resu	IT	:	No eye irritation	
Genta	amicin:			
Speci	ies	:	Rabbit	
Resu	It	:	Mild eye irritation	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 5.0	Revision Date: 06.04.2024		Number: 412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
betar	nethasone:			
Speci Resu			abbit o eye irritation	
Resp	iratory or skin sensi	tisation		
	sensitisation lassified based on ava	ailable inf	ormation.	
-	iratory sensitisation lassified based on ava		ormation.	
Com	ponents:			
Genta Rema	amicin: arks	: N	o data available	
betar	nethasone:			
Expos Speci Resu		: G	ermal Juinea pig /eak sensitizer	
	cell mutagenicity lassified based on ava	ailable inf	ormation.	
<u>Com</u>	ponents:			
	amicin:	-	· - · · ·	
Geno	toxicity in vitro		est Type: In vitro esult: negative	o mammalian cell gene mutation test
			est Type: Chrom esult: equivocal	nosome aberration test in vitro
Geno	toxicity in vivo	c S A	ytogenetic assay pecies: Mouse	nalian erythrocyte micronucleus test (in vivo /) : Intravenous injection
betar	nethasone:			
Geno	toxicity in vitro		est Type: Bacter esult: negative	ial reverse mutation assay (AMES)
			est Type: In vitro esult: negative	mammalian cell gene mutation test
			est Type: Chrom esult: positive	nosome aberration test in vitro
11				

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 5.0	Revision Date: 06.04.2024		OS Number: 73412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Geno	toxicity in vivo	:	Test Type: Mamm cytogenetic assay Species: Mouse Application Route Result: equivocal	
Germ sessr	cell mutagenicity- As- nent	:	Weight of evidend cell mutagen.	e does not support classification as a germ
	nogenicity assified based on availa	able	information.	
<u>Com</u>	ponents:			
	amicin: nogenicity - Assess-	:	No data available	
-	oductive toxicity damage the unborn child	١.		
<u>Com</u>	oonents:			
	amicin: is on fertility	:	Species: Rat Fertility: NOAEL:	eneration reproduction toxicity study 20 mg/kg body weight cant adverse effects were reported
Effect ment	s on foetal develop-	:	Species: Rabbit Developmental To Result: No embry	-
			Species: Rat Application Route	oxicity: LOAEL: 75 mg/kg body weight
			Species: Mouse Application Route Developmental To	o-foetal development : Intraperitoneal oxicity: LOAEL: 10 mg/kg body weight tality, No malformations were observed.
			Species: Rat Application Route Developmental To	o-foetal development : Intraperitoneal oxicity: LOAEL: 50 mg/kg body weight tality, No malformations were observed.



rsion)	Revision Date: 06.04.2024	SDS Numb 9373412-0	
Reproductive toxicity - As- sessment			e evidence of adverse effects on development from epidemiological studies.
betam	nethasone:		
Effects on foetal develop- ment		Applica Develo	s: Rabbit tion Route: Intramuscular omental Toxicity: LOAEL: 0.05 mg/kg body weight Fetotoxicity, Malformations were observed.
		Develo	s: Rat tion Route: Subcutaneous omental Toxicity: LOAEL: 0.42 mg/kg body weight Malformations were observed.
		Applica Develo	s: Mouse tion Route: Intramuscular omental Toxicity: LOAEL: 1 mg/kg body weight Malformations were observed.
	ductive toxicity - As-	: Clear e	vidence of adverse effects on development, based on
SESSIM STOT Not cla STOT	nent - single exposure assified based on avai - repeated exposure	animal lable informat	experiments.
STOT Not cla STOT Cause	nent - single exposure assified based on avai - repeated exposure	animal lable informat	experiments.
STOT Not cla STOT Cause <u>Comp</u>	nent - single exposure assified based on avai - repeated exposure es damage to organs t	animal lable informat	experiments.
STOT Not cla STOT Cause <u>Comp</u> Genta Targe	nent - single exposure assified based on avail - repeated exposure es damage to organs t ponents:	animal Iable informat hrough prolon : Kidney,	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated
sessm STOT Not cla STOT Cause Comp Genta Target Asses	nent - single exposure assified based on avai - repeated exposure es damage to organs t conents: amicin: t Organs	animal lable informat hrough prolon : Kidney, : Causes	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated
sessm STOT Not cla STOT Cause <u>Comp</u> Genta Targe Asses	nent - single exposure assified based on avail - repeated exposure es damage to organs to conents: amicin: t Organs ssment	animal lable informat hrough prolon : Kidney, : Causes exposu : Pituitar	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated re. y gland, Immune system, muscle, thymus gland, Blood
sessm STOT Not cla STOT Cause Comp Genta Target Asses betam	nent - single exposure assified based on avai - repeated exposure es damage to organs t conents: amicin: t Organs asment hethasone:	animal lable informat hrough prolon : Kidney, : Causes exposu : Pituitar Adrena	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated re. y gland, Immune system, muscle, thymus gland, Blood I gland damage to organs through prolonged or repeated
sessm STOT Not cla STOT Cause Comp Genta Targe Asses betam Targe	nent - single exposure assified based on avail - repeated exposure es damage to organs to conents: amicin: t Organs ssment hethasone: t Organs	animal ilable informat hrough prolon : Kidney, : Causes exposu : Pituitar Adrena : Causes	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated re. y gland, Immune system, muscle, thymus gland, Blood I gland damage to organs through prolonged or repeated
sessm STOT Not cla STOT Cause Comp Genta Targe Asses betam Targe Asses Repea	nent - single exposure assified based on avail - repeated exposure es damage to organs to conents: amicin: t Organs assment hethasone: t Organs ssment	animal ilable informat hrough prolon : Kidney, : Causes exposu : Pituitar Adrena : Causes	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated re. y gland, Immune system, muscle, thymus gland, Blood I gland damage to organs through prolonged or repeated
sessm STOT Not cla STOT Cause Comp Genta Targe Asses betam Targe Asses Repea	nent - single exposure assified based on avail - repeated exposure es damage to organs to conents: amicin: t Organs assment t Organs ssment ated dose toxicity	animal ilable informat hrough prolon : Kidney, : Causes exposu : Pituitar Adrena : Causes	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated re. y gland, Immune system, muscle, thymus gland, Blood I gland damage to organs through prolonged or repeated
sessm STOT Not cla STOT Cause Comp Genta Target Asses betam Target Asses Repea <u>Comp</u> Paraff	nent - single exposure assified based on avail - repeated exposure es damage to organs to conents: amicin: t Organs sment hethasone: t Organs sment ated dose toxicity conents: fin oil: es	animal lable informat hrough prolon : Kidney, : Causes exposu : Pituitar Adrena : Causes exposu : Rat, fer	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated re. y gland, Immune system, muscle, thymus gland, Blood I gland damage to organs through prolonged or repeated re.
sessm STOT Not cla STOT Cause Comp Genta Targe Asses betam Targe Asses Repea Comp Paraff Specie LOAE	nent - single exposure assified based on avail - repeated exposure es damage to organs to conents: amicin: t Organs sment hethasone: t Organs sment ated dose toxicity conents: fin oil: es	animal lable informat hrough prolon : Kidney, : Causes exposu : Pituitar Adrena : Causes exposu	experiments. ion. ged or repeated exposure. inner ear damage to organs through prolonged or repeated re. y gland, Immune system, muscle, thymus gland, Blood I gland damage to organs through prolonged or repeated re.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 5.0	Revision Date: 06.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Speci LOAE Applic Expos	EL cation Route sure time et Organs	: Dog : 3 mg/kg : Intramuscular : 12 Months : Kidney : Vomiting, Sali	vation
Expos		: Monkey : 50 mg/kg : Subcutaneous : 3 Weeks : Kidney, inner	
Expos		: Monkey : 6 mg/kg : Intramuscular : 3 Weeks : Blood, Kidney	, inner ear, Liver
Expos	EL	: Rat : 5 mg/kg : 10 mg/kg : Intramuscular : 52 Weeks : Kidney, Blood	
Expos	ΞL	: Rat : 12.5 mg/kg : 50 mg/kg : Intramuscular : 13 Weeks : Kidney	
Speci LOAE Applic Expos		: Rabbit : 0.05 % : Skin contact : 10 - 30 d : Pituitary glanc	I, Immune system, muscle
Expos		: Rat : 0.05 % : Skin contact : 8 Weeks : thymus gland	
Speci LOAE		: Mouse : 0.1 %	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Gentamicin / Betamethasone Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
Expos	cation Route sure time t Organs	: Skin contact : 8 Weeks : thymus gland	
Expos		: Dog : 0.05 mg/kg : Oral : 28 d : Blood, thymus	gland, Adrenal gland

Aspiration toxicity

Not classified based on available information.

Components:

Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

Experience with human exposure

Components:

Gentamicin:

Ingestion	 Target Organs: Kidney Target Organs: inner ear Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness
betamethasone:	
Inhalation	: Target Organs: Adrenal gland

Inhalation Skin contact	: Target Organs: Adrenal gland: Symptoms: Redness, pruritis, Irritation
----------------------------	--

SECTION 12: Ecological information

12.1 Toxicity

Components:

Paraffin oil:	
Toyicity to fich	

Toxicity to fish	:	LL50 (Scophthalmus maximus (turbot)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Acartia tonsa (Calanoid copepod)): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae/aquatic		EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 5.0	Revision Date: 06.04.2024		OS Number: 73412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
plants	5			h Vater Accommodated Fraction on data from similar materials
			Exposure time: 72 Test substance: V	ema costatum (marine diatom)): > 1 mg/l ? h Vater Accommodated Fraction on data from similar materials
Genta	amicin:			
	ity to daphnia and other tic invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
			LC50 (Americamy Exposure time: 96 Method: US-EPA	Sh T
Toxic plants	ity to algae/aquatic S	:	EC50 (Pseudokiro Exposure time: 72 Method: OECD Te	
			NOEC (Pseudokir µg/l Exposure time: 72 Method: OECD Te	
			EC50 (Anabaena Exposure time: 72 Method: OECD Te	
			NOEC (Anabaena Exposure time: 72 Method: OECD Te	
M-Fa icity)	ctor (Acute aquatic tox-	:	100	
Toxic	ity to microorganisms	:	EC50 : 288.7 mg/ Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
M-Fa	ctor (Chronic aquatic ty)	:	1	
betar	nethasone:			
	ity to daphnia and other tic invertebrates	:	EC50 (Americamy Exposure time: 96	
Toxic	ity to algae/aquatic	:	EC50 (Pseudokirc	chneriella subcapitata (green algae)): > 34

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 5.0	Revision Date: 06.04.2024	-	OS Number: 73412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
plant	S		mg/l Exposure time: 72 Method: OECD T Remarks: No toxi	
			mg/l Exposure time: 72 Method: OECD T	
Toxic icity)	city to fish (Chronic tox-	:	Exposure time: 32	2 d ales promelas (fathead minnow)
			NOEC: 0.07 µg/l Exposure time: 2 Species: Oryzias Method: OECD T	latipes (Japanese medaka)
aqua	city to daphnia and other tic invertebrates (Chron- kicity)	:	Exposure time: 27	magna (Water flea)
M-Fa toxic	actor (Chronic aquatic ity)	:	1,000	
12.2 Pers	sistence and degradabil	ity		
Com	ponents:			
	t amicin: egradability	:	Result: rapidly de Biodegradation: Exposure time: 28 Method: OECD T	100 % 3 d
12.3 Bioa	occumulative potential			
Com	ponents:			
Parti	ffin oil: tion coefficient: n- nol/water	:	log Pow: > 4 Remarks: Calcula	tion
Parti	t amicin: tion coefficient: n- nol/water	:	log Pow: < -2	
beta	methasone:			



Gentamicin / Betamethasone Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
	on coefficient: n- ol/water	: log Pow: 2.1	1
12.4 Mobility in soil No data available			
12.5 Resu	Its of PBT and vPvB	assessment	
<u>Produ</u>	<u>uct:</u>		
Asses	ssment	to be either	nce/mixture contains no components considered persistent, bioaccumulative and toxic (PBT), or ent and very bioaccumulative (vPvB) at levels of her.
12.6 Other	r adverse effects		
<u>Produ</u>	<u>uct:</u>		
Endoo tial	crine disrupting poten-	ered to have	nce/mixture does not contain components consid- endocrine disrupting properties for environment UK REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN	: UN 3077
ADR	: UN 3077
RID	: UN 3077
IMDG	: UN 3077
ΙΑΤΑ	: UN 3077

14.2 UN proper shipping name

: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 5.0	Revision Date: 06.04.2024		9S Number: 73412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
			(betamethasone,	Gentamicin)
ADR		:	ENVIRONMENTA N.O.S. (betamethasone,	ALLY HAZARDOUS SUBSTANCE, SOLID,
RID		:		ALLY HAZARDOUS SUBSTANCE, SOLID,
IMDG		:		ALLY HAZARDOUS SUBSTANCE, SOLID,
ΙΑΤΑ		:	Environmentally h (betamethasone,	nazardous substance, solid, n.o.s. Gentamicin)
14.3 Trans	sport hazard class(es)			
			Class	Subsidiary risks
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDG		:	9	
ΙΑΤΑ		:	9	
14.4 Packi	ing group			
Classi	ng group ification Code rd Identification Number s	:	III M7 90 9	
Classi Hazar Labels Tunne RID Packii Classi	el restriction code ng group ification Code rd Identification Number		III M7 90 9 (-) III M7 90 9	
Labels EmS (IATA	ng group s	:	III 9 F-A, S-F 956	



Gentamicin / Betamethasone Ointment Formulation

Ver 5.0	sion	Revision Date: 06.04.2024		DS Number: 373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021
		g instruction (LQ) g group	:	Y956 III Miscellaneous	
	Packin ger airc Packin	g instruction (LQ) g group	: : : :	956 Y956 III Miscellaneous	
14.	5 Enviro	onmental hazards			
	ADN Enviror	nmentally hazardous	:	yes	
	ADR Enviror	nmentally hazardous	:	yes	
	RID Enviror	nmentally hazardous	:	yes	
	IMDG Marine	pollutant	:	yes	
		Passenger) nmentally hazardous	:	yes	
		Cargo) nmentally hazardous	:	yes	
11	e Ennoir	al propoutions for use			

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) UK REACH Candidate list of substances of very high	:	Not applicable Not applicable
concern (SVHC) for Authorisation		
The Persistent Organic Pollutants Regulations (retained	:	Not applicable
Regulation (EU) 2019/1021 as amended for Great Brit-		
ain)		
Regulation (EC) No 1005/2009 on substances that de-	:	Not applicable
plete the ozone layer		



Gentamicin / Betamethasone Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 9373412-00007	Date of last issue: 30.09.2023 Date of first issue: 27.08.2021			
(Anne	ex XIV)	ces subject to authorisa				
	GB Export and import of hazardous chemicals - Prior : Not applicable Informed Consent (PIC) Regulation					
	· · · · ·	azards Regulations 20	015 (COMAH)			
E1	·	ENVIRONMEN HAZARDS	Quantity 1 Quantity 2 NTAL 100 t 200 t			

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version
		are highlighted in the body of this document by two vertical
		lines.

Full text of H-Statements

H304	:	May be fatal if swallowed and enters airways.
H330	:	Fatal if inhaled.
H360D	:	May damage the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.
H400	:	Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.
H413	:	May cause long lasting harmful effects to aquatic life.
Full text of other abbreviatio	ns	
Acute Tox.	:	Acute toxicity
Aquatic Acute	:	Short-term (acute) aquatic hazard
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Asp. Tox.	:	Aspiration hazard

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Gentamicin / Betamethasone Ointment Formulation

VersionRevision Date:SDS Number:Date of last issue: 30.09.20235.006.04.20249373412-00007Date of first issue: 27.08.2021	
---	--

Repr.:Reproductive toxicitySTOT RE:Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIOC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture:		Classification procedure:	
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/	

Classification of the m	ixture:	Classification procedur		
Repr. 1B	H360D	Calculation method		
STOT RE 1	H372	Calculation method		
Aquatic Chronic 1	H410	Calculation method		

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.



Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	9373412-00007	Date of first issue: 27.08.2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN